# A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

> **NCT06441084** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Nuwacell Biotechnologies Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** NCR300 injection

## Key facts

- **NCT ID:** NCT06441084
- **Lead sponsor:** Nuwacell Biotechnologies Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-30
- **Primary completion:** 2028-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441084, "A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06441084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*